Table 3

 Standardised mortality ratios and 95% CIs of patients with rheumatoid arthritis treated or not with tumour necrosis factor antagonists with respect to the expected rate in the general population of Spain

BIOBADASEREMECARMortality rate ratios*
Mortality ratios and 95% CIs (BIOBADASER/EMECAR).
*Adjusted by age and sex.
†p<0.001.
All causes0.516 (0.315 to 0.797)1.493 (1.174 to 1.872)0.32 (0.20 to 0.53)†
    Men0.469 (0.152 to 1.095)1.548 (1.059 to 2.185)
    Women0.534 (0.299 to 0.881)1.455 (1.053 to 1.960)
Cardiovascular0.510 (0.205 to 1.050)0.937 (0.546 to 1.450)0.58 (0.24 to 1.41)
    Men1.281 (0.349 to 3.281)1.227 (0.530 to 2.417)
    Women0.283 (0.058 to 0.826)0.774 (0.354 to 1.470)
Infectious11.294 (4.541 to 23.270)18.676 (10.210 to 31.335)0.52 (0.21 to 1.29)
    Men5.589 (0.142 to 31.141)10.069 (2.077 to 29.427)
    Women13.609 (4.994 to 29.622)24.352 (12.156 to 43.572)
Cancer0.284 (0.059 to 0.831)0.988 (0.526 to 1.689)0.36 (0.10 to 1.30)
    Men0.000 (0.000 to 0.952)1.660 (0.829 to 2.970)
    Women0.450 (0.093 to 1.314)0.306 (0.037 to 1.106)